MPN Pomalidomid Multi-Center Phase II Study with Pomalidomide in Patients with Myeloproliferative Neoplasms in Fibrotic Stage.
{"Image DocumentName": "MPN PomalidomidMulti-Center Phase II Study with Pomalidomide in Patients with Myeloproliferative Neoplasms in Fibrotic Stage.", "Image ImageDescription": "If no CR, PR, CI, TI. Einschlusskriterien. diagnosis of MPN. de novo myelofibrosis according to WHO criteria. secondary myelofibrosis (post-PV and post ET MF according to the IWG.MRT consensus terminology) unclassifiable MPN with biopsy proven myelofibrosis. Ausschlusskriterien. BCR/ABL positivity. > 20% blasts in periperal blood or bone marrow. history of thrombosis or pulmonary embolism Prednisolon 10. If no CR, PR, CI, TI. 30. R. 15. Prednisolon 10. Pomalidomide 0,5 mg p.o. (Continuation of treatment if no pomalidomide induced toxicity and no PD) Cycles. Rekrutierung: Beginn Ende 12/2013 Patientenzahl: 57 Ansprechpartner: PI Dr. Philippe Schafhausen SI Dr. Gunhild Keller et al SK Ramona Michallik \u00a9 Block/K\u00f6sters. Version 1.0 \u2013", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}